Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
July 21 — The European Medicines Agency (EMA) July 21 released proposed changes to its guidance on first-in-human (FIH) clinical trials in the wake of a trial-related death in January.
The changes are outlined in a concept paper that the agency released for public comments, which are due by Sept. 30.
The review of the guidance was partly prompted by the death of one participant and the hospitalization of five others in a phase I FIH clinical trial in Rennes, France, in January (10 LSLR 02, 1/22/16).
Ironically, the incident parallels the near-fatal injuries in a London-based clinical trial in 2006 that spurred the EMA to issue the guidance in 2007.
The EMA noted in the concept paper that the revision also was prompted by changes since 2007 in the integration of non-clinical data that are available before an FIH trial and the pharmacokinetic (PK, what happens to the drug in the human system), pharmacodynamic (PD, the relationship between the drug and the patient's response) and human safety data emerging during the trial.
Mark Barnes of Ropes & Gray LLP, Boston, told Bloomberg BNA in a July 21 e-mail, “Additional attention to how to design first-in-human trials safely and with optimal attention to PK and PD data and data from animal models, is welcome, particularly in light of the dawn of the use of gene therapy agents as disease treatments.”
Barnes added that when the guidance is revised, “[W]e can expect not only additional regulatory attention to early phase studies but also additional attention to late phase, post-approval studies, all to gather more, better and more timely information about safety issues.”
The concept paper outlines discussion points for consideration in revising the 2007 guidance:
The concept paper was prepared by an EU-wide expert group that includes experts from national authorities that authorize clinical trials in the EU, and it was adopted by the EMA's Committee for Medicinal Products for Human Use.
The drug being tested in the January incident in Rennes was for mood disorders and was developed by Portuguese-based pharmaceutical company Bial, with the test conducted by Biotrial, a clinical research organization based in Rennes.
The EMA document was guided by the findings from two in-depth investigations into the Rennes trial, one carried out by the Temporary Specialist Scientific Committee set up by the French medicines agency ANSM, and the other by the Inspection générale des affaires sociales, the French inspector general for social affairs.
The U.S. Food and Drug Administration commented that catastrophic adverse events in phase I studies conducted in the U.S. are extremely rare due to the safety data the agency requires for submitting an investigational new drug application (10 LSLR 03, 2/5/16).
It added that it is collecting and reviewing safety data in connection with the Rennes trial and working with the EMA and ANSM.
The events in Rennes that helped spur the revision of the guidance parallel those that prompted its creation in 2007.
In April 2006, in the London-based FIH trial of TGN412, a monoclonal antibody developed as a medicine to treat leukemia and other autoimmune diseases, all six volunteers suffered multiple organ failure, requiring intensive therapy.
A working group was established that produced a report , which resulted in a revision of the Association of British Pharmaceutical Industries' guidance for phase I clinical trials and the current EMA guidance, “Guidelines on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products,” in 2007.
Comments on the concept paper's proposals should be sent by Sept. 30 to FIHemail@example.com.
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
The concept paper is at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500210825.pdf.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)